KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Apr 30, 2025. Filed Jul 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jul 17, 2025
KMTS$29.55-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year Ended April 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $59,815 | $27,814 |
| Cost of revenue | 35,605 | 27,452 |
| Gross profit | 24,210 | 362 |
| Operating expenses: | ||
| Research and development | 15,652 | 15,490 |
| Selling, general and administrative | 114,936 | 69,935 |
| Total operating expenses | 130,588 | 85,425 |
| Loss from operations | (106,378) | (85,063) |
| Other expense (income): | ||
| Interest expense | 7,734 | 6,230 |
| Interest income | (3,199) | — |
| Other expense | 2,766 | 2,803 |
| Net loss before provision for income taxes | (113,679) | (94,096) |
| Provision for income taxes | 135 | 24 |
| Net loss and comprehensive loss | (113,814) | (94,120) |
| Less: Undeclared preferred stock dividends | 12,321 | 6,721 |
| Net loss attributable to common shareholders, basic and diluted | $(126,135) | $(100,841) |
| Net loss per share attributable to common shareholders, basic and diluted | $(5.13) | $(5.07) |
| Weighted-average shares of common shares outstanding, basic and diluted1 | 24,583,745 | 19,885,382 |
1 Weighted-average shares of common shares outstanding, basic and diluted, has been adjusted on a retrospective basis. Refer to Note 16 “Net Loss Per Share Attributable to Common Shareholders” for additional disclosure.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.